Florquinitau

Summary

Florquinitau (CHEMBL4804173) is a phase-3 clinical-stage small molecule; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 278.28 Da · C16H11FN4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4804173
Name	Florquinitau
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	118577045
Molecular formula	C16H11FN4
Molecular weight	278.28
InChIKey	KAXAUWZJVWGFDO-UHFFFAOYSA-N

SMILES: C1=CC(=C(C2=CC(=NC=C21)N3C=CC4=C3C=NC=C4)N)F

IUPAC name: 6-fluoro-3-pyrrolo[2,3-c]pyridin-1-ylisoquinolin-5-amine

Also known as: Florquinitau, MK-6240, FLORQUINITAU, US10022461, Compound 18

Parent form; salt/anhydrous children: CHEMBL4802252

Patent coverage: 55 distinct patent families (129 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 113 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Microtubule-associated protein tau.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPT	9.37	Ki	0.43	nM	CHEMBL_ACT_26909637

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Alzheimer disease	1	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06600880	PHASE1	NOT_YET_RECRUITING	Neuronavigation-guided FUS-induced BBB Opening in Alzheimer’s Disease Patients and Its Effects on Brain Amyloid and Tau
NCT05617014	Not specified	ENROLLING_BY_INVITATION	Alzheimer’s Disease Neuroimaging Initiative 4

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).